Immunotherapy in advanced non-small-cell lung cancer (NSCLC) after progression on chemotherapy: real-world results from a prospective institutional cohort

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Wu YL, Planchard D, Lu S et al. Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann. Oncol. 30(2), 171–210 (2019). • This article highlights the consensus opinion of experts on the treatment of metastatic non-small-cell lung cancer (NSCLC) in Asian patients. Notably, the invited experts did not represent India, where unique challenges exist towards guideline adoption, but nevertheless provide a framework for further adaptation towards more localized needs.
  MedlineGoogle Scholar
• 2. Horn L, Spigel DR, Vokes EE et al. Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35(35), 3924–3933 (2017). •• The updated results of these multi-national trials demonstrate long-term efficacy of nivolumab compared to docetaxel in previously treated advanced squamous and non-squamous NSCLC. Less than 3% of trial participants in both trials were of Asian descent, while none were from India.
  Medline CASGoogle Scholar
• 3. Mencoboni M, Ceppi M, Bruzzone M et al. Effectiveness and safety of immune checkpoint inhibitors for patients with advanced non small-cell lung cancer in real-world: review and meta-analysis. Cancers (Basel) 13(6), 1388 (2021). • This meta-analysis of real world studies provides evidence of benefit with PD-1/PD-L1 inhibitors in patients who would be considered ineligible for clinical trial inclusion.
  Medline CASGoogle Scholar
• 4. Gyawali B, Bouche G, Crisp N, André N. Challenges and opportunities for cancer clinical trials in low-and middle-income countries. Nat. Cancer 1, 142–145 (2020).
  MedlineGoogle Scholar
• 5. Singh N, Agrawal S, Jiwnani S et al. Lung cancer in India. J. Thorac. Oncol. 16(8), 1250–1266 (2021).
  MedlineGoogle Scholar
• 6. Jain E, Sharma S, Aggarwal A et al. PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: an Indian perspective. Pathol. Res. Pract. 228, 153497 (2021).
  Medline CASGoogle Scholar
• 7. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 389(10082), 1885–1906 (2017).
  MedlineGoogle Scholar
• 8. Mohan A, Garg A, Gupta A et al. Clinical profile of lung cancer in north India: a 10-year analysis of 1862 patients from a tertiary care center. Lung India 37(3), 190–197 (2020).
  MedlineGoogle Scholar
• 9. Dietel M, Savelov N, Salanova R et al. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study. Lung Cancer 134, 174–179 (2019).
  Medline CASGoogle Scholar
• 10. Graham RP, Treece AL, Lindeman NI et al. Worldwide frequency of commonly detected EGFR mutations. Arch. Pathol. Lab. Med. 142(2), 163–167 (2018).
  Medline CASGoogle Scholar
• 11. Vashistha V, Choudhari C, Garg A et al. The time required to diagnose and treat lung cancer in Delhi, India: an updated experience of a public referral center. Appl. Cancer. Res. 39, 11 (2019).
  Google Scholar
• 12. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 13. Seymour L, Bogaerts J, Perrone A et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18(3), e143–e152 (2017).
  MedlineGoogle Scholar
• 14. Vandenbroucke JP, von Elm E, Altman DG et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 4(10), e297 (2007).
  MedlineGoogle Scholar
• 15. Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21(13), 2529–2536 (2003).
  Medline CASGoogle Scholar
• 16. Goldberg SB, Schalper KA, Gettinger SN et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 21(5), 655–663 (2020). •• This open-label trial provides evidence of benefit with PD-1 inhibition in patients with at least one brain metastases smaller than 2 cm in size.
  Medline CASGoogle Scholar
• 17. Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am. Soc. Clin. Oncol. Educ. Book 35, 185–198 (2016).
  MedlineGoogle Scholar
• 18. Wu YL, Lu S, Cheng Y et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized Phase III clinical trial. J. Thorac. Oncol. 14(5), 867–875 (2019).
  Medline CASGoogle Scholar
• 19. Shaverdian N, Lisberg AE, Bornazyan K et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 Phase 1 trial. Lancet Oncol. 18(7), 895–903 (2017). •• This secondary analysis of KEYNOTE-001 demonstrated the value of delivering thoracic radiotherapy prior to PD-1 inhibition and paved the way for several ongoing clinical trials investigating the combination of radiotherapy and ICI.
  Medline CASGoogle Scholar
• 20. Patel RR, Verma V, Barsoumian H et al. Use of multi-site radiation therapy as systemic therapy: a new treatment approach personalized by patient immune status. Int. J. Radiat. Oncol. Biol. Phys. 109(2), 352–364 (2021). •• This article provides a comprehensive review on the role of radiotherapy in activating the immune system and offers a hypothetical framework for conducting future research on the topic.
  MedlineGoogle Scholar
• 21. Theelen WSME, Chen D, Verma V et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir. Med. 9(5), 467–475 (2021).
  Medline CASGoogle Scholar
• 22. Ye H, Pang H, Shi X et al. Nivolumab and hypofractionated radiotherapy in patients with advanced lung cancer: ABSCOPAL-1 Clinical Trial. Front. Oncol. 11, 657024 (2021).
  MedlineGoogle Scholar
• 23. Mitchell P, O'Byrne KJ, Brown C et al. A randomized phase 2 trial of nivolumab and stereotactic ablative body radiotherapy (SABR) in advanced non-small cell lung cancer, progressing after first-or second-line chemotherapy (NIVORAD). Int. J. Radiat. Oncol. Biol. Phys. 111(3), S10–S11 (2021).
  Google Scholar
• 24. Kepka L, Cieslak E, Bujko K, Fijuth J, Wierzchowski M. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis. Acta Oncol. 44(4), 389–398 (2005).
  MedlineGoogle Scholar
• 25. Sperduto PW, Yang TJ, Beal K et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 3(6), 827–831 (2017).
  MedlineGoogle Scholar
• 26. Petrelli F, De Stefani A, Trevisan F et al. Combination of radiotherapy and immunotherapy for brain metastases: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 144, 102830 (2019).
  MedlineGoogle Scholar
• 27. Berghoff AS, Inan C, Ricken G et al. Tumor-infiltrating lymphocytes (TILs) and PD-L1 expression in non-small cell lung cancer brain metastases (BM) and matched primary tumors (PT). Ann. Oncol. 25, iv465–iv470 (2014).
  Google Scholar
• 28. Portnow J, Wang D, Blanchard MS et al. Systemic anti–PD-1 immunotherapy results in PD-1 blockade on T Cells in the cerebrospinal fluid. JAMA Oncol. 6(12), 1947–1951 (2020).
  MedlineGoogle Scholar
• 29. Gondi V, Paulus R, Bruner DW et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of radiation therapy oncology group randomized trials 0212 and 0214. Int. J. Radiat. Oncol. Biol. Phys. 86(4), 656–664 (2013).
  MedlineGoogle Scholar